Certain Breast CA Patients Benefit From Adjuvant Capecitabine
Capecitabine cut risk of relapse, death by 30 percent over five years, researchers say
Three-Drug Combo Pill Nearly 100 Percent Effective in Curing Hep C
Pill (sofosbuvir, velpatasvir, voxilaprevir) is for patients who have failed with direct-acting antivirals
Medication Adherence Up With Refill Synchronization Model
Improvement in medication-taking behavior; cost savings over one year for HTN, DM, hyperlipidemia
Excess Weight Increases Costs Across Health Care Settings
Percentage increases in costs associated with obesity were highest for medications, higher for women
High Costs for Myeloma Patients Not Getting Low-Income Subsidy
For those aged 75 to 84 years, LIS receipt linked to increased odds of receiving immunomodulatory drugs
Modified Vancomycin May Help Fight Bacterial Resistance
New form of vancomycin attacks bacteria in three ways, helping curb threat of microbial resistance
Restarting Anticoagulation in Certain VTE Cases Cost-Effective
Treating patients with predicted VTE risk of 17.5 percent or more may be cost-effective
Severe Cutaneous Adverse Effect From Tocilizumab Described
Diffuse, persistent, pruritic maculopapular rash developed 10 days after tocilizumab treatment
~4 Percent of U.S. Population Has Food Allergy, Intolerance
Researchers find most common food allergen groups are shellfish, fruit or vegetable, dairy, and peanut
Evacetrapib Appears Futile in High-Risk Vascular Disease
No reduction in primary end point events, including death from cardiovascular causes, MI, stroke
